Elysium Health and Long-Term Healthy Living

There is a vast supplement market fueled by health-conscious people seeking the nutrition needed to live healthier and longer lives. The myriad of options and the impossibility of taking all of them at once create substantial confusion about how to prioritize what is really helpful. Ads pushing unverified claims hardly clarify anything.

Elysium Health appears to offer promise for an oasis in this desert. The credibility of any business starts with the quality of its leadership and staff. Consumer health company Elysium Health was co-founded by an MIT scientist and has on its advisory board more than two dozen renowned scientists and clinicians from the world’s leading academic institutions. They guide the direction of the company and its research.

According to their website, “Elysium’s mission is to solve the biggest challenges in health with science , to help people live healthier, longer. Specifically, their goal is to take the findings from scientific research and translate them into health products that work.

Elysium Health points out that “cellular health is the foundation of overall health.” A coenzyme known as NAD+ (nicotinamide adenine dinucleotide) is critical to cellular health. Cells need proteins called sirtuins to maintain homeostasis under stress, and they cannot function without NAD+. NAD+ is essential for hundreds of biological processes including turning nutrients into energy, maintaining the health of DNA, and regulating circadian rhythms. .

As we age, we have less NAD+ in our cells, and this appears to explain a lot about why the aforementioned functions decline. Elysium’s first product, Basis, is designed to support cellular health and clinically proven to increase levels of NAD+.

Elysium’s clinical trial demonstrated that Basis safely increased NAD+ levels in humans by an average of 40 percent within four weeks. The increase was sustained for the duration of the trial.

Basis contains the  active ingredients nicotinamide riboside and pterostilbene.

The ingredients in Basis have been tested for safety and are produced in facilities that meet FDA requirements. No animal products are used in Basis. Basis also undergoes rigorous third party purity testing.

Elysium’s website sells Basis in bottles containing 60 capsules, a one-month supply. The recommended dosage is two capsules each morning. Pricing range from $40 per bottle for a one-year subscription ($480) with monthly delivery to $60 for an individual bottle.


Dr. Clay Siegall, Ph.D. offers a great new hope for cancer patients.

Dr. Clay Siegall, Ph.D. developed an intense enthusiasm for genetics early on in his journey to become the career scientific researcher he is today. He earned a Bachelor of Science Degree in Zoology from the University of Maryland and his Ph.D. in Genetics from George Washington University. From there he went on to immerse himself further when he went to work for the National Cancer Institute of Health during the years 1988 to 1991 followed by a six year stint at the Bristol-Meyers Squibb Pharmaceutical Research Institute from 1991 to 1997. Having gained enormously more knowledge and training greatly focused on cancer treatment therapies; he went on to become the co-founder, Chief Executive Officer, and Chairman of the Board of the currently globally recognized biotechnology corporation, Seattle Genetics, that was incorporated in 1998.


As the Co-founder and Chief Executive Officer of Seattle Genetics, Dr. Clay Siegall, Ph.D. demonstrated an unparalleled passion for helping patients who had the misfortune of being diagnosed with cancer. He created and environment receptive to exploratory minds committed to meticulous research and disciplined practices in the search of innovative scientific discoveries related to cancer treatments. The focuses of this endeavor lead to the groundbreaking discovery of antibody drug conjugates or ADCs.


Since the discovery of ADCs, Dr. Clay Siegall, Ph.D. has broadened the horizons of Seattle Genetics to include even greater discoveries and applications in conjunctive collaboration involving other biotechnology and pharmaceutical companies. ADCs have quickly inspired a variety of new cancer treatments that span a widening spectrum of cancers in over sixty countries.


In addition to the accomplishments of Seattle Genetics gained under the leadership and guidance of Dr. Clay Siegall, Ph.D., he has authored over seventy publications and secured fifteen product patents to date. He has been recognized as the recipient of the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year and the 2013 University of Maryland Alumnus of the Year for Computer, Math, and Natural Sciences awards. He has enthralled internet and written publication media outlets throughout the world as they anticipate the next wave of greatness from this extraordinary mind.